Biotech

BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus and secure full rights to a leading prospect in the white-hot immuno-oncology space.

Medable is bringing generative AI into its clinical trial platform in hopes that the tech will reduce the burden of repetitive tasks on trial sponsors, the company announced in a Nov. 12 release

There's a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Ovid Therapeutics is pumping the brakes on a planned phase 2 trial for its ROCK2 inhibitor in a type of brain lesion while it considers any lessons to be learned from the mixed readout of Recursion's rival candidate.

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 million series B fundraise

Syros Pharmaceuticals' blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping 85% off the share price of the beleaguered biotech.

After laying off all nonessential workers and halting nonessential R&D work this summer, Entero Therapeutics is inking a reverse merger with antibody drug conjugate (ADC) rival biotech Journey Therapeutics.

Caris Life Sciences has obtained an FDA approval for its MI Cancer Seek tumor profiling assay, unlocking its use as a companion diagnostic for multiple targeted medications across several cancers.

Adaptimmune Therapeutics is prepping for another FDA submission after 42% of patients with sarcoma responded to the company's investigational cell therapy in a pivotal phase 2 trial.

Gubra's once-weekly obesity candidate was tied to 3% weight loss during a six-week phase 1 trial, with a single injection also linked to weight reduction.